Myocarditis
Conditions
Brief summary
To study the value of heart rate lowering therapy pharmacological rest on the short term in cases of myocarditis without LV dysfunction.
Interventions
DRUGIvabradine
heart rate lowering therapy
Sponsors
Assiut University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Adults: ≥18 years of age. * Presentation: at least one of the following: * Myopericarditis/ACS-like * MINOCA * Arrhythmias: brady or tachyarrhythmias. * Unexplained compensated acute cardiomyopathy (excluded ischemic, valvular, hypertensive, metabolic, and toxic causes of cardiomyopathy as indicated clinically). * TTE: LVEF\>40% * CMR-confirmed myo(peri)carditis (Lake Louise criteria)
Exclusion criteria
* • Rheumatic carditis. * Connective tissue diseases (-ve ANA). * Cancer chemotherapy. * Toxicity from immunotherapy. * Vaccine-related myocarditis. * Presence of coronary artery disease. * Peripartum (occurring during the last month of pregnancy or within 5 months after delivery) * ECG: atrial fibrillation/flutter. * Resuscitated sudden death. * Early/initial phase of decompensated heart failure. * Tamponade complicating pericarditis unless successfully managed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Value of Heart Rate Lowering Therapy in Acute Myocarditis | baseline | To study the value of heart rate lowering therapy pharmacological rest on the short term in cases of myocarditis without LV dysfunction. |
Countries
Egypt
Contacts
Primary Contactsara mahmoud
Outcome results
None listed